aminoglycoside

(redirected from Aminoglycosides)
Also found in: Medical.
Related to Aminoglycosides: Macrolides, Aminoglycoside antibiotics

a·mi·no·gly·co·side

 (ə-mē′nō-glī′kə-sīd′, ăm′ə-)
n.
Any of a group of broad-spectrum antibiotics, such as streptomycin, derived from species of Streptomyces or Micromonospora bacteria and used to treat infections caused by gram-negative bacteria.
Mentioned in ?
References in periodicals archive ?
4] Enterococci are resistant to a number of antimicrobial agents including [beta]-lactam antibiotics, glycopeptides and aminoglycosides.
CDC investigators found the Klebsiella pneumoniae, which the woman contracted in India, totally resistant to 26 antibiotics, including all aminoglycosides and polymyxins, and intermediately resistant to tigecycline (a tetracycline derivative).
Gentamicin is one of the most commonly used aminoglycosides against enterococcus, since its discovery in 1963.
Aminoglycosides are active against many aerobic Gram-negative bacteria, some aerobic Gram-positive bacteria, and certain mycobacteria.
Objective: Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections.
In Iran, 22% of samples were reported positive and containing sulfonamides of which 1% contained aminoglycosides and no sample contained [beta]-lactams, tetracyclines or macrolides [8].
Aminoglycosides are used either alone or in combination with [beta]-lactams as effective agents for treating such infections (1).
Among the most powerful weapons in our antibiotic arsenal are aminoglycosides, which can prevent the biosynthesis of key proteins that infectious bacteria such as Staphylococcus aureus and Escherichia coli need to survive.
Although high concentrations of aminoglycosides, despite the use of standard doses corrected for Cr-based GFR estimates, may indicate renal impairment, this is akin to shutting the stable door long after the horse has gone.
Aminoglycosides are a broad-spectrum class of Gram-negative antibiotics that are a mainstay in the hospital setting.
We evaluated the ototoxic effect of aminoglycosides on the outer hair cells of newborns in a neonatal intensive care unit (NICU) by means of distortion-product otoacoustic emissions (DPOAE) testing.